DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...
DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...
DexCom is a leader in the continuous glucose monitoring (CGM) systems market. They aren't the only kinds of devices that help diabetes patients keep track of their blood glucose levels -- a necessary ...
DexCom, Inc. reduced its 2024 revenue guidance following a decline in new U.S. customers and revenue per customer, leading to a sharp share price drop, despite $750 million share buyback. DexCom faces ...
DexCom's Q2 earnings report was disastrous, revealing internal sales channel issues and competitive pressures, leading to a Hold rating and lowered price targets. The company's reliance on channel ...
DexCom , Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) systems for diabetes management with a market ...
DexCom's returns over the past decade have been solid, but not quite on par with the market's. The company has encountered some headwinds in recent years that have sunk its stock price. Despite the ...
DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results